Muscarinic Agonists

Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate.

Also Known As:

Cholinergic Agonist, Muscarinic; Cholinergic Muscarinic Agonists; Muscarinic Agonist; Agonist, Muscarinic; Agonist, Muscarinic Cholinergic; Agonists, Cholinergic Muscarinic; Agonists, Muscarinic; Agonists, Muscarinic Cholinergic; Muscarinic Agonists, Cholinergic; Muscarinic Cholinergic Agonist; Muscarinic Cholinergic Agonists; Cholinergic Agonists, Muscarinic

Networked: 386 relevant articles (23 outcomes, 42 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Cholinergic Agents: 12323
        Cholinergic Agonists: 312
        Muscarinic Agonists: 386
  - Physiological Effects of Drugs: 1
    - Neurotransmitter Agents: 13181
      - Cholinergic Agents: 12323
        Cholinergic Agonists: 312
        Muscarinic Agonists: 386

Experts

1.	Fisher, Abraham: 6 articles (07/2008 - 08/2002)
2.	Messer, William S: 5 articles (03/2014 - 04/2002)
3.	Sales, María E: 4 articles (01/2020 - 07/2007)
4.	Jones, Carrie K: 4 articles (01/2012 - 09/2001)
5.	Fisher, A: 4 articles (01/2002 - 01/2000)
6.	Sales, María Elena: 3 articles (06/2021 - 01/2013)
7.	Español, Alejandro J: 3 articles (01/2020 - 07/2007)
8.	Nathanson, Neil M: 3 articles (02/2015 - 04/2003)
9.	Felder, Christian C: 3 articles (07/2014 - 04/2003)
10.	Chen, Hong-Zhuan: 3 articles (08/2013 - 07/2003)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/2002 - "Impact of muscarinic agonists for successful therapy of Alzheimer's disease." 03/01/2000 - "Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors." 08/01/2002 - "Recent studies suggesting a role for muscarinic agonists in regulating the production of A beta raise the possibility that selective M1 agonists could be useful in treating not only the symptoms, but also the underlying cause(s) of Alzheimer's disease. " 10/09/1990 - "Although a number of muscarinic agonists have been used in clinical trials for Alzheimer's Disease, many of these compounds are low in potency and have only limited intrinsic efficacy. " 10/01/1984 - "After toxicity studies in dogs, a preliminary feasibility trial of the continuous intracranial infusion of a muscarinic agonist was begun in four patients with biopsy-documented Alzheimer's disease. "
2.	Schizophrenia (Dementia Praecox) 01/01/2012 - "Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions." 11/01/2008 - "Muscarinic agonists for the treatment of cognition in schizophrenia." 07/01/2014 - "The M(4) receptor is a compelling therapeutic target, as this receptor modulates neural circuits dysregulated in schizophrenia, and there is clinical evidence that muscarinic agonists possess both antipsychotic and procognitive efficacy. " 10/30/2009 - "Arecoline, a partial muscarinic agonist, has been hypothesized to have beneficial effects on both positive and negative symptoms of schizophrenia. " 01/01/2009 - "Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia."
3.	Cognitive Dysfunction 03/01/2000 - "Cholinergic neurons degenerate in Alzheimer's disease, resulting in cognitive impairments and memory deficits, and drug development efforts have focused on selective M1 muscarinic agonists. " 03/01/2005 - "Collectively, the present findings demonstrate that a functional interaction occurs between the muscarinic cholinergic and dopaminergic systems in modulating PPI and that muscarinic cholinergic agonists may be effective in the treatment of the PPI and other cognitive impairments observed in schizophrenia." 09/01/2011 - "Earlier, we have shown that oxotremorine, a cholinergic muscarinic agonist, ameliorates stress-induced cognitive impairment and restores cholinergic function. " 01/01/2002 - "The M1 muscarinic agonists AF102B, AF150(S) & AF267B--i) restored cognitive impairments in several animal models for AD with an excellent safety margin; ii) elevated alpha-APPs levels; iii) attenuated vicious cycles induced by A beta, and inhibited A beta- and oxidative stress-induced apoptosis; and iv) decreased tau hyperphosphorylation. "
4.	Chronic Pain 09/01/2007 - "Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain." 12/20/2001 - "Selective muscarinic agonists could be useful in the treatment of neurological disorders such as Alzheimer's disease, schizophrenia, and chronic pain. " 01/01/1999 - "Thus, muscarinic cholinergic agonists and cholinesterase inhibitors hold promise as non-opiate agents for the treatment of moderate to severe acute and chronic pain." 09/25/2003 - "Muscarinic agonists might be useful in the treatment of neurological disorders, including Alzheimer's disease, schizophrenia, chronic pain, and drug abuse. "
5.	Nervous System Diseases (Neurological Disorders) 09/25/2003 - "Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders." 12/20/2001 - "Selective muscarinic agonists could be useful in the treatment of neurological disorders such as Alzheimer's disease, schizophrenia, and chronic pain. " 01/01/2004 - "Bivalent ligands represent an important starting point for the development of selective muscarinic agonists with potential utility in treating a variety of neurological disorders, including Alzheimer's disease and schizophrenia. " 09/25/2003 - "Muscarinic agonists might be useful in the treatment of neurological disorders, including Alzheimer's disease, schizophrenia, chronic pain, and drug abuse. " 01/01/2012 - "Conversely, both direct-acting muscarinic receptor agonists and indirect-acting muscarinic cholinergic agonists, such as acetylcholinesterase inhibitors, have shown cognition-enhancing properties, including improvements in normal cognitive function, reversal of cognitive deficits induced by muscarinic receptor antagonists, and attenuation of cognitive deficits in psychiatric and neurological disorders, such as Alzheimer's disease and schizophrenia. "

Related Drugs and Biologics

1.	Cholinergic Agents (Cholinergics)
2.	xanomeline
3.	Pilocarpine (Ocusert)
4.	Carbachol (Carbastat)
5.	Muscarinic Antagonists
6.	Arecoline (Arecolin)
7.	2- ethyl- 8- methyl- 2,8- diazaspiro(4,5)decane- 1,3- dione (RS 86)
8.	Oxotremorine
9.	Bethanechol (Duvoid)
10.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Anesthesia
4.	Intravenous Injections
5.	Injections